Bayer Ag · XETR:BAYN

Bayer — 23rd European Society of Retina Specialists (EURETINA) Congress 2023

10 slides from Bayer's conference presentation, October 2023

  1. Slide 1: Subgroup Analyses from the Phase 3 PULSAR Trial of Aflibercept 8 mg in nAMD

    Subgroup Analyses from the Phase 3 PULSAR Trial of Aflibercept 8 mg in Patients with Treatment-Naïve Neovascular Age-Related Macular Degeneration Oliver Zeitz,1 Sobha Sivaprasad,2 Sergio Leal,3 Tobias Machewitz,4 Xin Zhang,3 on behalf of the PULSAR study investigators 1Department of Ophthalmology, C

  2. Slide 2: Disclosures

    Disclosures nAMD • OZ: Consultant and speaker for Allergan, Bayer, Boehringer Ingelheim, and Novartis; is a consultant for Omeicos and Oxular; and receives research support from Bayer, Boehringer Ingelheim, and Novartis. Employment with Bayer ended September 30, 2016 o SS: receives funding/fees from

  3. Slide 3: PULSAR Study Design

    PULSAR Study Design Multicenter, randomized, double-masked study in patients with treatment-naive nAMD Randomized at baseline 1 (2q8) : 1 (8q12) : 1 (8q16) 2q8 Aflibercept 2 mg every 8 weeks after 3 initial monthly injections n=336 Primary endpoint at Week 48 Mean change in BCVA (non-inferiority) Ke

  4. Slide 4: PULSAR: Dosing Schedule and Regimen Modification in Year 1

    PULSAR: Dosing Schedule and Regimen Modification in Year 1 nAMD

  5. Slide 5: BCVA by Baseline BCVA Categories (ETDRS Letters): At Week 48

    BCVA by Baseline BCVA Categories (ETDRS Letters): At Week 48 nAMD

  6. Slide 6: BCVA by Baseline CST Categories (µm): At Week 48

    BCVA by Baseline CST Categories (µm): At Week 48 nAMD

  7. Slide 7: BCVA by Baseline CNV Type: At Week 48

    BCVA by Baseline CNV Type: At Week 48 nAMD

  8. Slide 8: BCVA by Race: At Week 48

    BCVA by Race: At Week 48 nAMD Change from Baseline at Week 48a

  9. Slide 9: Proportion of Patients Maintaining 8 mg Q12 and Q16 Treatment Intervals Up to Week 48

    Proportion of Patients Maintaining 8 mg Q12 and Q16 Treatment Intervals Up to Week 48: nAMD Categorized by Race

  10. Slide 10: Conclusions: Baseline Subgroup Analyses at Week 48 nAMD

    Conclusions: Baseline Subgroup Analyses at Week 48 nAMD • BCVA outcomes were comparable for aflibercept 8 mg vs aflibercept 2 mg among the evaluable subgroups of baseline characteristics • Regardless of differences in baseline BCVA and BCVA change at Week 48 in some subgroups, absolute BCVA values a

Bayer — 23rd European Society of Retina Specialists (EURETINA) Congress 2023 on 6ix